Clinical Trials Sponsored by Shionogi Inc.

Total 35683 results

Shionogi

Completed

Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions

Cerebral Palsy | Sialorrhea | Mental Retardation | Neurological Conditions

United States
Shionogi
Integrium

Completed

A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia

Combined Hyperlipidemia

United States
Shionogi
QuatRx Pharmaceuticals

Completed

Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus

Atrophy | Vaginal Diseases
Shionogi
QuatRx Pharmaceuticals

Completed

Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus

Atrophy | Vaginal Diseases
Shionogi
Eli Lilly and Company

Completed

A Study of Duloxetine (LY248686) in Japanese Children and Adolescents With Depressive Disorder

Depressive Disorder

Japan
Shionogi
Merck Sharp & Dohme LLC

Recruiting

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (aCCeleR8-001)

Solid Tumors

United States, Japan
Shionogi
Eli Lilly and Company

Terminated

A Study of Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents With Depressive Disorder

Depressive Disorder

Japan
Shionogi
Hormos Medical; QuatRx Pharmaceuticals

Completed

Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity

Atrophy | Vaginal Diseases
Shionogi
Hormos Medical; QuatRx Pharmaceuticals

Completed

A Clinical Study to Evaluate the Safety of Ospemifene

Atrophy | Vaginal Diseases
Shionogi
Hormos Medical; QuatRx Pharmaceuticals

Completed

A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women

Atrophy | Vaginal Diseases
Shionogi
Hormos Medical; QuatRx Pharmaceuticals

Completed

A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women

Atrophy | Vaginal Diseases
Hartford Hospital
Shionogi Inc.

Active, not recruiting

Cefiderocol Plasma Concentrations in Patients Receiving Renal Replacement Therapy

Pharmacokinetics

United States
Plethora Solutions Ltd
Shionogi Inc.

Completed

Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation

Premature Ejaculation

United States
Shionogi
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19 (SCORPIO-HR)

SARS-CoV-2 Infection

United States, India, Uganda, Poland, Philippines, Thailand, Pakistan, South Africa, Argentina, Brazil, Colombia, Ghana, Japan, Kenya, Malawi, Mexico, Turkey
GlaxoSmithKline
Shionogi

Completed

A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected Patients

HIV Infections

United States
GlaxoSmithKline
Shionogi

Completed

GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study

Healthy Volunteer

United States
GlaxoSmithKline
Shionogi

Completed

GSK1349572 Drug Interaction Study With Atazanavir/Ritonavir and Atazanavir

Healthy Volunteer

United States
GlaxoSmithKline
Shionogi

Completed

Study to Assess Cardiac Conduction of GSK1349572

Healthy Subjects

United States
GlaxoSmithKline
Shionogi

Completed

GSK1349572 Mass Balance Study

Healthy Volunteer

United States
GlaxoSmithKline
Shionogi

Completed

GSK1349572 Drug Interaction Study With Etravirine

Healthy Subjects

United States
AstraZeneca
Shionogi

Completed

Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease

Hypercholesteremia

Japan
GlaxoSmithKline
Shionogi

Completed

GSK1349572 Drug Interaction Study With Protease Inhibitors

Healthy Subjects | Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline
Shionogi

Completed

A Study to Evaluate the Effect of Antacid and Multivitamin and Mineral Tablet on the Study Drug GSK1349572 (DDI)

Healthy Volunteer

United States
ViiV Healthcare
Shionogi

Completed

GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir

Healthy Volunteer

United States
ViiV Healthcare
Shionogi

Completed

A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects

Infections, Human Immunodeficiency Virus and Hepatitis

United States
University of Florida
Shionogi Inc.; The PBCers Organization

Completed

Use of Fenofibrate for Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
Joseph L. Kuti, PharmD
Shionogi Inc.

Recruiting

Cefiderocol PK in Patients on ECMO

Sepsis

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults (SAILING)

HIV Infections | Infection, Human Immunodeficiency Virus

United States, France, Netherlands, Spain, Taiwan, Australia, Belgium, Russian Federation, Canada, United Kingdom, Mexico, Italy, South Africa, Romania, Argentina, Hungary, Poland, Chile, Greece, Brazil
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

GSK1349572 Hepatic Impairment Study

HIV Infections | Healthy Subjects | Hepatic Impairment | Infection, Human Immunodeficiency Virus

United States
Purdue Pharma LP
Shionogi

Completed

A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the Knee

Osteo Arthritis Knee

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects (ING112276)

Infection, Human Immunodeficiency Virus

United States, Spain, France, Germany, Italy, Russian Federation
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Evaluation of the Bioequivalence of a Combined Formulated Tablet

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects

Infections, Human Immunodeficiency Virus and Tuberculosis

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Dolutegravir Renal Impairment Study

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349572 (Dolutegravir, DTG) in Healthy Japanese Subjects

Infection, Human Immunodeficiency Virus

United States
Hoffmann-La Roche
Shionogi

Completed

Study to Assess the Pharmacokinetics, Safety and Tolerability of Baloxavir Marboxil in Healthy Chinese Participants

Healthy Volunteer

China
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers (ING)

HIV Infections | Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

Infection, Human Immunodeficiency Virus I

United States, Spain, Germany, Australia, Canada, Belgium, Denmark, Netherlands, United Kingdom, France, Italy, Romania
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

GSK1349572 Drug Interaction Study With Efavirenz

Infections, Human Immunodeficiency Virus and Herpesviridae

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen. (VIKING-3)

Infection, Human Immunodeficiency Virus

United States, Spain, France, Canada, Portugal, Italy, Belgium
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Drug Interaction Study Between Dolutegravir and Prednisone

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets

Healthy Subjects | Infection, Human Immunodeficiency Virus

United States
Qpex Biopharma, Inc.
Shionogi Inc.; Biomedical Advanced Research and Development Authority

Recruiting

P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants

Bacterial Infections

Australia
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily (SPRING-2)

Infection, Human Immunodeficiency Virus I

Germany, Spain, France, Australia, United States, Canada, United Kingdom, Italy, Russian Federation
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir (VIKING-4)

HIV Infections

United States

Clinical Trials Sponsored by Shionogi Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations